Concordia International Corp | StockChase
202
Concordia International Corp (CXR-T)

Last Price Recorded: $0.6000 on 2017-11-20

ON STOCKCHASE SINCE Mar 2014

Formerly Concordia Healthcare Corp

Pharma & Healthcare

Concordia International Corp


Signal Opinion Expert

2017-11-16

WATCH
Concordia International Corp (CXR-T)

You likely can’t salvage anything from here.  If you are interested in this stock then wait for it to have a couple of positive quarters and let the chart be your guide. 

Pharma & Healthcare
Fabrice Taylor

Publisher, The President's Club Newsletter

Price: $0.620
Owned: Unknown

2017-11-13

BUY
Concordia International Corp (CXR-T)

It is a very Canadian story.  They are a drug manufacturer that were hit in a wave that took down others.  He does not follow it closely, but a number of these stories have the ability to reconstitute themselves.  They can find a way to make money at it or find someone to take them over.

Pharma & Healthcare
Brendan Caldwell

President, Caldwell Securities

Price: $0.680
Owned: Unknown

2017-10-18

SELL
Concordia International Corp (CXR-T)

It has lost the overwhelming majority of its value.  It is burdened with leverage.  It is important to step back and take a cold, clinical view of it.  The market does not care what you paid for it.  The prospects going forward don’t look very favourable for it.  The subordinate debt went into default this week.  The stock is more of a lottery ticket.

Pharma & Healthcare
Brian Madden

Senior VP & Portfolio Manager, Goodreid Investment Council

Price: $1.210
Owned: Unknown

2017-10-11

DON'T BUY
Concordia International Corp (CXR-T)

She wouldn’t be buying this now, even though the stock price has come down dramatically from what it was a few years ago. This has only been public for about 4-5 years, and they’ve been buying assets. There is a lot of pricing pressure on the drugs they bought and paid a lot for. Has a lot of debt on their balance sheet. Debt to Enterprise EBITDA is over 11X. There is a big question as to how they are going to repay the debt when it comes due. Based on what they have now, it doesn’t seem sufficient.

Pharma & Healthcare
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $1.490
Owned: No

2017-10-05

WAIT
Concordia International Corp (CXR-T)

He loves turnaround stories with lots of debt. When you get them right, they really move. This one is not a turnaround yet. It has a lot of things that you look for, what it doesn’t have are signs of a turnaround. Wait until you see two quarters of deleveraging and improving margins. The stock will move from there. It still has bankruptcy risks.

Pharma & Healthcare
Fabrice Taylor

Publisher, The President's Club Newsletter

Price: $1.590
Owned: Unknown

2017-09-20

PAST TOP PICK
Concordia International Corp (CXR-T)

(A Top Pick June 21/16. Down 95%.) He sold this before the end of last year.

Pharma & Healthcare
Zachary Curry

Chief Operating Officer & Portfolio Manager, Davis-Rea Ltd.

Price: $1.520
Owned: No

2017-09-12

DON'T BUY
Concordia International Corp (CXR-T)

Doesn’t think this is investable. Net debt to EBITDA is about 11X, which is very high. They have absolutely no visibility in terms of pricing in the UK, because the whole pricing regime is changing. She can’t see how they are going to pay the debt which comes due in 2021.

Pharma & Healthcare
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $1.620
Owned: No

2017-06-23

COMMENT
Concordia International Corp (CXR-T)

He is pessimistic on this. They recently hired another set of advisors to advise them on capital structure. That usually doesn’t end well for equity holders. Just had so much debt. The big UK acquisition they made really went south on them in a hurry. Expects debt holders are either going to want a massive equity dilution or for some kind of bankruptcy and restructuring. The equity is probably close to worthless.

Pharma & Healthcare
James Hodgins

Chief Investment Officer, Curvature Hedge Strategies

Price: $1.710
Owned: Unknown

2017-05-09

COMMENT
Concordia International Corp (CXR-T)

This as not an investable name. They borrowed money to make a UK acquisition and are having issues with that.

Pharma & Healthcare
Lyle Stein

Sr. Portfolio & Managing Director, Vestcap Investment Management

Price: $2.850
Owned: No

2017-04-11

PAST TOP PICK
Concordia International Corp (CXR-T)

(A Top Pick March 3/16. Down 95%.) About 9 months ago, he advised his members that it was time to move on from this name.

Pharma & Healthcare
Ryan Modesto

Managing Partner, 5i Research

Price: $1.860
Owned: No

2017-02-23

DON'T BUY
Concordia International Corp (CXR-T)

Technically it has fallen off the face of the earth.  You are making a gamble at this point.  He would not move into healthcare at this time of the year.

Pharma & Healthcare
Brooke Thackray

President, Jov Investment Management

Price: $3.070
Owned: Unknown

2017-02-22

COMMENT
Concordia International Corp (CXR-T)

If looking to be exposed to all the positive attributes about global healthcare, this is not a company he would be focusing on.

Pharma & Healthcare
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $3.070
Owned: Unknown

2017-02-01

DON'T BUY
Concordia International Corp (CXR-T)

Concordia (CXR-T) or Valeant (VRX-T)? He wouldn’t pick either because whenever you have accounting irregularities, that never gets better, especially in Canada. This sector is under so much heat right now. The US president has really focused in on even legitimate drug companies and there is going to be a lot of scrutiny. doesn’t think either will survive.

Pharma & Healthcare
Brendan Caldwell

President, Caldwell Securities

Price: $2.900
Owned: No

2017-01-05

WAIT
Concordia International Corp (CXR-T)

It is dead money.  This has been a disaster.  You are going to see a lot of write-offs from this company.  You have to wait for the write-offs.  His model price is a little misnomer.  You could hold it if you own it.

Pharma & Healthcare
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $2.900
Owned: Unknown

2016-12-23

SELL
Concordia International Corp (CXR-T)

A lot of people took a bath this year. There were a few additional issues that came up. BREXIT hurt them more than expected. The acquisition of Amco was based primarily in Britain, and the currency translation really hurt. Also, they have generic competition for some of their US drugs. When you have a large debt outstanding, there is no room in your equity. Sold his holdings in the high teens. He doesn’t know if they will survive. Take a tax loss today, and then later on you can buy it back.

Pharma & Healthcare
John Zechner

Chairman, J. Zechner & Assoc

Price: $2.910
Owned: No

Showing 1 to 15 of 202 entries
<< < 1 2 3 4 5 > >>
Post Comment

5 Comments

uptick

October 14th 2015 at 7:14am

I hope this company drops to zero for ethical reasons.

barney11

October 21st 2015 at 1:41pm

I do not invest in healthcare but seeing this zero comment (meaningless) and watching BNN interview the CEO of Concordia today I must comment. My concern is BNN is starting to act more like FOX TV for negative sensation than ever before. We know you are intelligent A, you do not have to prove yourself by subtly attacking the interviewee with 100% negativity. One positive question would make your approach more credible.

Martin Gutnik, LL.B.

September 17th 2016 at 6:30am

To the point raised by barney11 on October 21, 2015 - I must credit the BNN interview of the CEO and agree with BNN (and disagree with barney 11) that the only useful way to present information in a fair manner is to ask the hard questions and play devils advocate. You can be certain that executives form companies that are publicly traded will offer up the best spin on everything to entice buyers of their company stock. To be fair - they must be challenged. There are people out there investing their hard earned dollars and they deserve to know the downside risks. If anything - I find that the interviews are too soft on the executives. But made for television analysis must be kind or else there would be few guests to interview. By the way - look at the collapse of this particular stock and tell me now that you think the interview was too negative!!!!

Martin Gutnik, LL.B.

September 17th 2016 at 6:30am

To the point raised by barney11 on October 21, 2015 - I must credit the BNN interview of the CEO and agree with BNN (and disagree with barney 11) that the only useful way to present information in a fair manner is to ask the hard questions and play devils advocate. You can be certain that executives form companies that are publicly traded will offer up the best spin on everything to entice buyers of their company stock. To be fair - they must be challenged. There are people out there investing their hard earned dollars and they deserve to know the downside risks. If anything - I find that the interviews are too soft on the executives. But made for television analysis must be kind or else there would be few guests to interview. By the way - look at the collapse of this particular stock and tell me now that you think the interview was too negative!!!!

barney11

September 17th 2016 at 3:51pm

Martin, a year later you missed the point and obviously did not watch the interview. Would you have bothered to make your comment if CRX was up $100."A" has not repeated the same approach since, and I believe she is maturing in her assignment.


You must be logged in to comment.